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Abstract The new and growing family of interleukin-l~- 
converting enzyme (ICE) cysteine proteases are now recognised 
to be major effectors of cellular death by apoptosis. Like other 
members of this family, the CPP32/Yama proform is activated 
by processing to its active heterodimeric enzyme or apopain when 
it likely contributes to the process of apoptosis by cleaving 
poly(ADP-ribose) polymerase (PARP) and thereby inhibiting 
much of its DNA repair activity. Apoptosis plays a fundamental 
role in the regulation of the immune system where it is involved in 
the selection of both T and B lymphocytes bearing antigen 
receptor (AgR) for non-self. Cells of the Ramos Epstein-Barr 
virus (EBV)-genome-negative Burkitt lymphoma (BL) B cell line 
(Ramos-BL) can be triggered into growth arrest and apoptosis by 
treating with the calcium ionophore ionomycin or by cross- 
linking their surface AgR with antibodies directed against 
immunoglobulin (Ig)M (anti-IgM). Ionomycin- and AgR-trig- 
gered growth arrest and apoptosis are arrested by signals 
transduced through the surface CD40 of Ramos-BL B cells. Both 
ionomycin and anti-IgM trigger activation of CPP32 and 
cleavage of PARP prior to the onset of apoptosis; this process 
is abrogated by treatment with anti-CD40 and is independent of 
Bcl-2 expression. A tripeptide inhibitor of ICE family cysteine 
proteases, Z-Val-Ala-Asp-fluoromethylketone (zVAD-fmk) in- 
hibits ionomycin- and AgR-triggered CPP32 activation, PARP 
cleavage and apoptosis, but not growth arrest, in Ramos-BL B 
cells. Thus, in this report we demonstrate that in a physiological 
system, activation of endogenous members of the ICE family, 
including CPP32, and cleavage of the death substrate PARP act 
as major effectors of apoptotic death. 
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1. Introduction 
Apoptosis is a highly conserved form of cell death which 
plays a fundamental role in development, homeostasis and in 
the regulation of the immune system [1,2]. The concept hat 
the mechanism of apoptosis is conserved erives from obser- 
vations consistently demonstrating that all mammalian cells 
undergoing this form of death exhibit common morphological 
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characteristics [3,4]. These features include cellular shrinkage, 
membrane blebbing, chromatin condensation and degradation 
and culminate with the rapid phagocytosis of the apoptotic 
cells or their fragments by neighbouring cells or professional 
phagocytes [1-4]. Conservation of the molecular machinery of 
apoptosis also finds strong support from studies of pro- 
grammed cell death in the nematode Caenorhabditis elegans. 
Here, the protein products of ced-3 and ced-4 are required for 
all somatic deaths that occur during the development of this 
nematode, while the ced-9 gene product affords protection 
from ced-3- and ced-4-induced eath. The Ced-9 protein is 
homologous to mammalian Bcl-2, a proto-oncogene product 
that affords protection against apoptosis, such that the func- 
tion of mutationally inactivated ced-9 can be partially restored 
by expression of the human bcl-2 gene [5]. Although no mam- 
malian homologues of Ced-4 have been discovered to date, 
Ced-3 exhibits homology to the new and growing family of 
interleukin-ll3-converting e zyme (ICE) cysteine proteases [6- 
9]. 
The ICE family is now known to comprise at least five 
members including CPP32/Yama/apopain [10-12], Nedd-2/ 
ICH-1 [13,14], TX/ICH-2/ICErealI [15-17], ICErellII [17] and 
Mch-2 [18]; Fernandes-Alnemri et al. [19] and Duan et al. [20] 
have recently described novel additions to the family, Mch-3 
and ICE-LAP3 respectively, which are closely related to 
CPP32/Yama. All family members to date are synthesised as 
proenzymes that are proteolytically processed to form active 
heterodimeric proteases that contain the pentameric peptide, 
QACRG, which surrounds the putative catalytic residue cys- 
teine [10-20]. Ectopic expression of ICE and its relatives re- 
suits in the apoptosis of a variety of host cells which can be 
arrested by the cowpox serpin Crm A or by tetrapeptide 
(YVAD) inhibitors of ICE-like proteases [14,21,22]. 
The article now presented queries how ICE and its family 
members contribute to the process of apoptosis: although yet 
to be elucidated, it is thought hat the activation of a cascade 
of proteases and the subsequent proteolytic leavage of their 
specific substrates likely leads to the structural changes or to 
the activation of other effectors critical for death [4]. It is 
known that ICE-like proteases degrade lamins during apop- 
tosis and may thereby trigger collapse of the chromatin 
[23,24]. A partially characterised 24-kDa protease has been 
shown to induce DNA degradation characteristic of apoptosis 
when added to purified nuclei possibly by activating an en- 
donuclease as it does not itself exhibit any nuclease activity 
[25]. Activated CPP32/Yama or apopain can cleave po- 
ly-(ADP-ribose) polymerase (PARP) and thereby inhibit 
most of its DNA repair activity [11,12,18,19,26]. 
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Fig. 1. Anti-CD40 inhibits ionomycin- and anti-IgM-triggered 
CPP32 processing and apoptosis in Ramos-BL B cells. Ramos-BL B 
cells (3× 105ceUs/ml) were cultured for 18, 24, 30, 36 and 48 h alone 
or with ionomycin (1 ~tg/ml) or with anti-IgM (20 ~tg/ml) in the ab- 
sence or presence of anti-CD40 (1 p.g/ml) and expression of the 
CPP32 proform determined by immunoblotting. The results of one 
experiment, representative of two, are shown and the CPP32 pro- 
form is denoted by an arrow. 
In this study, we investigate CPP32/Yama/apopain- 
mediated cleavage of PARP as a putative effector of apoptosis 
in a cell line model of B lymphocyte selection during matura- 
tion of the humoral immune response. Briefly, in the germinal 
centres (GC) of secondary lymphoid tissues, B cells undergo 
somatic hypermutation on their immunoglobulin (Ig) variable 
genes and are selected for expression of  high-affinity antigen 
receptor (AgR), which comprises Ig, for non-self by compet- 
ing for limited antigen: non-selected GC B cells are deleted by 
apoptosis and removed by tingible body macrophages [27-29]. 
A vestige of this normal selection process appears to be re- 
tained in Burkitt lymphoma (BL) B cells which are Epstein- 
Barr virus (EBV)-genome-negative such as Ramos (Ramos- 
BL). Not  only do these cells express a phenotype character- 
istic of GC B cells but they also readily undergo apoptosis in 
response to a number of stimuli including calcium ionophore. 
However, in marked contrast o GC B cells antibody directed 
against Ig actually drives apoptosis in these cells [30]. Ligation 
of the type I surface glycoprotein CD40 delivers a survival 
signal in both normal and neoplastic B cell types [29,30]. 
We now present evidence that signals transduced through 
CD40 [30] or treatment with the zVAD- fmk tripeptide inhibi- 
tors of the ICE-family cysteine proteases [31,32] prevent cal- 
cium ionophore- and AgR-triggered processing of CPP32, 
cleavage of PARP and apoptosis in Ramos-BL B cells. 
2. Materials and methods 
2.1. Reagents, antibodies and their sources 
2.1.1. Reagents. Benzyloxycarbonyl-valinyl-alaninyl-aspartyl( O- 
methyl)-fluoromethylketone (zVAD-fmk), a cell-permeable, irreversi- 
ble tripeptide inhibitor of the ICE family of cysteine proteases, was 
supplied by Enzyme Systems Products, Inc. (Dublin, CA, USA). Io- 
nomycin was obtained from Calbiochem (Nottingham, UK) and di- 
methyl sulphoxide (DMSO) from Sigma (Poole, UK). Stock solutions 
ofzVAD-fmk (50 mM in DMSO) and ionomycin (1 mg/ml in ethanol) 
were kept at -20°C and final dilutions made immediately prior to use. 
[3H]Thymidine (185 GBq/mmol) and the enhanced chemiluminescence 
(ECL) Western blotting system were purchased from Amersham Life 
Science (Aylesbury, UK). 
2.1.2. Antibodies. The sheep polyclonal antibodies to human IgM 
(anti-la-chain-specific) was obtained from The Binding Site Ltd (Bir- 
mingham, UK). The murine monoclonal antibody to human CD40 
(G28.5) was purified from the supernatant of hybridoma HB9110 
(American Type Culture Collection, Rockville, MD, USA). The sheep 
anti-mouse Ig horseradish peroxidase (HRP)-linked whole antibody 
was purchased from Amersham. The mouse monoclonal antibody to 
human CPP32 was supplied by Transduction Laboratories (Lexing- 
ton, KY, USA). The mouse monoclonal antibody to mammalian 
PARP (anti-PARP) was kindly donated by Professor W.C. Earnshaw 
of The Institute of Molecular and Cellular Biology, The University of 
Edinburgh (UK). The mouse monoclonal antibody to human Bcl-2 
(anti-Bcl-2) was a kind gift from Dr. D.Y. Mason of The Department 
of Cellular Science, John Radcliffe Hospital, Oxford (UK). 
2.2. BL cell lines 
The BL B cell line used in this study, Ramos-BL, is EBV-genome- 
negative and was derived from a 3-year-old Caucasian male with 
histologic diagnosis of American BL [33-35]. The Ramos-BL B cell 
line was obtained from the European Collection of Animal Cell Cul- 
tures (Porton Down, Salisbury, UK). These cells were maintained in 
exponential culture in RPMI 1640 medium supplemented with 10% 
heat-inactivated fetal calf serum (hiFCS) from pre-screened batches. 
Table 1 
Anti-CD40 rescues Ramos-BL B cells from ionomycin- and anti-IgM-triggered growth arrest 
Time (h) [3H]thymidine incorporation (cpm) 
Con aCD40 Iono Iono algM algM 
+ + 
~CD40 ~CD40 
18 11 926 11 624 7 529 8266 4719 4741 
24 37 754 18 993 8 373 13 626 12 109 13 592 
30 38 944 30 806 9 823 19 647 23 323 30 544 
36 39 801 32 967 17 643 26 162 21 642 19 740 
48 71 831 36 722 14400 29 401 22 801 31 809 
Ramos-BL B cells (3 × 105cells/ml) were cultured alone, or with ionomycin (Iono, 1 p~g/ml) or with anti-IgM (algM, 20 ~tg/ml) in the absence or 
presence of anti-CD40 (o~CD40, 1l.tg/ml) for the appropriate time and [3H]thymidine incorporation was assessed uring the last 4 h of culture. The 
results of one experiment, representative of two, are presented as mean counts per minute (cpm) for triplicate cultures with standard eviation 
typically less than 15%. 
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2.3. Cell culture 
Ramos-BL B cells (3 x l0 s cells/ml) were established in RPMI 1640 
medium enriched with 10% hiFCS (CM) in 24-well (for samples for 
Western blotting) and 96-well (for measurement of [3H]thymidine in- 
corporation and apoptosis) flat-bottomed microculture plates in du- 
plicate and triplicate respectively at37°C, 5%, CO2 for the appropriate 
time. 
2.4. Assessment of DNA synthesis 
DNA synthesis was determined for the final 4 h of incubation for 
Ramos-BL B cell culture by pulsing each well with 0.5 p, Ci (18.5 kBq) 
of [3H]thymidine contained in 50 Ixl of CM. 
2.5. Detection of apoptosis 
Ramos-BL B cell apoptosis quantified routinely by flow cytometry 
(Becton Dickinson FACScan analyzer, Oxford, UK) as previously 
described [30,36]. The results presented are expressed as percent apop- 
totic events which is calculated from the proportion of cellular events 
classified as apoptotic for each culture. 
2.6. Detection of CPP32, PARP and Bcl-2 by Western blotting 
CPP32, PARP and Bcl-2 were detected by immunoblotting with the 
appropriate murine monoclonal ntibodies. Briefly, 6 x 105 Ramos-BL 
B cells per sample were pelleted by microfuge, washed twice with PBS 
and resuspended in 50 ~1 SDS-sample buffer. Samples for detection of 
PARP were run on 7.5% SDS-polyacrylamide g ls and samples for 
detection of CPP32 and Bcl-2 on 14% SDS-polyacrylamide g ls. Fol- 
lowing transfer to nitrocellulose membrane, the immunoblots were 
blocked by incubating with 5% milk in Tris-HC1 pH 7.5 with 0.1% 
Tween 20 and probed for 2 h at room temperature or overnight at 
4°C with murine anti-CPP32 (0.25 pg/ml) or with murine anti-PARP 
(1 in 2000) or with murine anti-Bcl-2 (1 in 20) diluted to the appro- 
priate concentration i Tris-HCl pH 7.5 with 0.1% Twcen 20 and 
0.001% sodium azide. The immunoblots were then probed with 
HRP-conjugated anti-mouse Ig (1 in 7500 in 5% milk in Tris-HC1 
pH 7.5) and developed using the ECL system. 
3. Results 
3.1. Anti-CD40 inhibits ionomycin- and anti-IgM-triggered 
CPP32 processing and apoptosis in Ramos-BL B cells 
We have previously shown that cells of the EBV-genome- 
negative Ramos-BL B cell line can be rescued from calcium 
ionophore- and surface IgM (sIgM)-triggered growth arrest 
and apoptosis by signals transduced through the type I sur- 
face glycoprotein CD40 [30]. To determine whether the cys- 
teine protease CPP32, which is highly expressed in cell lines of 
lymphocytic origin [10] including Ramos-BL (Fig. 1), is a 
component of the ionomycin- and sIgM-triggered pathway(s) 
leading to apoptosis, we assessed expression of the endoge- 
nous CPP32 proform for Ramos-BL B cells cultured alone or 
Table 2 
Anti-CD40 rescues Ramos-BL B cells from ionomycin- and anti- 
IgM-triggered apoptosis 
Time (h) Percent apoptotic events 
Con c~CD40 Iono Iono cdgM ~tIgM 
+ + 
~CD40 ~CD40 
18 7.2 9.8 30 16 12 16 
24 6.3 9.6 35 19 14 19 
30 7.3 11 46 20 17 16 
36 4.2 9.0 54 23 20 15 
48 2.6 4.9 67 25 27 11 
Ramos-BL B cells (3x 10%ells/ml) were cultured as described for 
Table 1 and apoptosis was quantified by flow cytometry following 
the appropriate incubation period. The results of one experiment, 
representative of two, are presented as percent apoptotic events for 
pooled triplicate cultures. 
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Fig. 2. Anti-CD40 inhibits ionomycin- and anti-IgM-triggered cleav- 
age of PARP in Ramos-BL B cells. Ramos-BL B cells were cultured 
as described for Fig. 1 and expression of PARP was determined by 
immunoblotting. The results of one experiment, representative of
two, are shown. The 130-kDa PARP is denoted by an arrow and 
its 89-kDa fragment by an arrowhead. 
with ionomycin or anti-IgM in the absence or presence of 
anti-CD40 over a 48-h culture period. 
Ramos-BL B cells treated with ionomycin exhibit a signifi- 
cant decrease from 18- to 48-h culture of detectable levels of 
CPP32 proenzyme, presumably reflecting activation by pro- 
cessing to its 17-kDa and 12-kDa subunits which comprise 
apopain [12]; these data are consistent with our findings 
that ionomycin induces significant growth arrest (Table 1) 
and apoptosis (Table 2) by 18-h culture with maximal effect 
achieved by 48 h. Anti- IgM also triggers a steady decrease in 
detectable levels of the CPP32 proform from 24 h post stimu- 
lation, which is consistent with the ability of anti-IgM to in- 
duce significant apoptosis of Ramos-BL B cells from 30-h 
culture; the late onset of apoptosis likely reflects our findings 
that anti-IgM-induced apoptosis is linked to the cell cycle [30]. 
Since anti-IgM induces growth arrest as early as 18 h, it is 
likely that this AgR-triggered pathway is distinct from that to 
CPP32 activation and apoptosis. 
Co-culture with anti-CD40 significantly reduces ionomycin- 
triggered processing of CPP32 and abrogates anti-IgM-trig- 
gered CPP32 cleavage over the 48-h culture period. This is 
consistent with our data that treatment of Ramos-BL B cells 
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Table 3 
zVAD-fmk does not inhibit ionomycin- and anti-IgM-triggered 
growth arrest in Ramos-BL B cells 
zV AD-fmk 
(/~M) 
[3H]Thymidine incorporation (cpm) 
Exp. 1 Exp. 2 Exp. 3 
Con 0 58632 63435 45196 
10 67252 62423 39788 
50 61 809 68934 54086 
100 75378 70842 54115 
Table 4 
zVAD-fmk inhibits ionomycin- and anti-IgM-triggered apoptosis in 
Ramos-BL B cells 
zVAD-fmk Percent apoptotic events 
(BM) 
Exp. 1 Exp. 2 Exp. 3 
Con 0 11 7.5 4.1 
10 10 6.5 3.5 
50 8.3 5.4 3.0 
100 9.0 5.3 3.2 
Iono 0 10265 9756 12900 
10 11271 12193 16561 
50 8 025 12785 9897 
100 12083 7895 12138 
Iono 0 52 73 67 
10 48 73 60 
50 47 47 34 
100 33 25 21 
algM 0 29364 21186 27995 
10 24001 22051 28477 
50 14903 12 247 13 718 
100 22016 17666 22184 
Ramos-BL B cells (3 × 105cells/ml) were cultured alone, or with iono- 
mycin (Iono, 1 Bg/ml) or with anti-IgM (0dgM, 20 ~tg/ml) in the 
absence or presence of zVAD-fmk (10-100 BM) and [3H]thymidine 
incorporation was assessed uring the last 4 h of a 48-h culture. The 
results of three experiments are presented as mean counts per minute 
(cpm) for triplicate cultures with standard eviation typically less than 
15%. 
with anti-CD40 significantly enhances the proliferative capa- 
city and viability of those cells cultured with calcium iono- 
phore or with anti-IgM. 
3.2. Anti-CD40 inhibits ionomycin- and anti-IgM-triggered 
cleavage of  PARP in Ramos-BL B cells 
In order to confirm that ionomycin and anti-IgM trigger 
activation of CPP32 and that the observed ecrease in detect- 
able levels of CPP32 can be attributed to processing of the 
proenzyme to its active apopain form [12], we investigated 
expression of PARP, which is cleaved from a l l3-116-kDa 
form to an 85-89-kDa fragment by CPP32 [11,12,26,37]. 
As shown in Fig. 2 PARP is expressed as a single polypep- 
tide protein of 130 kDa, a slightly higher molecular weight 
than that reported by others [11,12,26,37], in untreated and 
anti-CD40-stimulated Ramos-BL B cells over a 48-h culture 
period. By contrast, anti-IgM triggers cleavage of PARP, as 
witnessed by increasing levels of the 89-kDa cleavage frag- 
ment, and this is abrogated by co-culture with anti-CD40. 
While our observations that anti-IgM-triggered cleavage of 
PARP, apparent by 18-h culture, precedes activation of 
CPP32, which is not apparent until 30 h, may reflect the 
different sensitivities of the antibodies used for immunoblot- 
ting or differences in concentrations of protein expressed, it 
may also indicate that signals transduced through sIgM acti- 
vate another member of  the ICE family that is able to cleave 
PARP, prior to activation of CPP32. We favour the latter of 
these alternatives ince ionomycin, which clearly activates 
CPP32 activation by 18 h, does not induce cleavage of 
PARP until 30 h and thus precludes the possibility that dif- 
ferences in the sensitivities of our assays for CPP32 and PARP 
cleavage account for our observations. The data obtained 
from ionomycin-treated cultures raise the possibility that 
CPP32 activated by an ionomycin-triggered pathway acts on 
a substrate other than PARP. As for anti-IgM, anti-CD40 is 
able to at least partially inhibit ionomycin-triggered cleavage 
of PARP. 
cdgM 0 47 51 26 
10 41 42 21 
50 35 36 20 
100 31 32 16 
Ramos-BL B cells (3× 105cells/ml) were cultured as described for 
Table 3 and apoptosis was quantified by flow cytometry following 
48-h culture. The results of three experiments are presented as percent 
apoptotic events for pooled triplicate cultures. 
3.3. Anti-CD40-mediated inhibition of  ionomycin- and 
anti-lgM-triggered CPP32 processing and PARP cleavage 
occurs independently of  Bcl-2 expression 
Although it is now well established that expression of the 
26-kDa protein product of the bcl-2 proto-oncogene can af- 
ford protection against apoptosis [5], it is as yet unclear at 
which specific step in the apoptotic pathway Bcl-2 may act: 
Kumar [38] has postulated that Bcl-2 may inhibit activation of 
ICE family members by subverting upstream signal transduc- 
tion events or by blocking proteolytic leavage of these cys- 
teine proteases to their active forms or by sequestering their 
downstream targets. We decided to address this issue by mon- 
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Fig. 3. Anti-CD40-mediated inhibition of ionomycin- and anti-IgM- 
triggered CPP32 processing and PARP cleavage occurs indepen- 
dently of Bcl-2 expression. Ramos-BL B cells were cultured as de- 
scribed for Fig. 1 and expression of Bcl-2 was determined by immu- 
noblotting. The results of one experiment, representative of two, are 
shown and Bcl-2 is denoted by an arrow; negative (-ve) controls 
comprise time zero samples of Ramos-BL B cells and positive (+ve) 
controls comprise Ramos-BL B cells stimulated for 48 h with anti- 
CD40 (1 Bg/ml). 
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itoring expression of Bcl-2 in Ramos-BL B cells cultured on 
their own or with ionomycin or anti-IgM in the absence or 
presence of anti-CD40 (Fig. 3). 
We were unable to detect Bcl-2 by immunoblotting in con- 
trol untreated as well as in ionomycin- and anti-IgM-treated 
Ramos-BL B cells cultured over a 48-h period. However, ex- 
pression of Bcl-2 became apparent from 36 h on culture of 
Ramos-BL B cells with anti-CD40 alone or with ionomycin 
and anti-CD40. Since treatment with anti-CD40 prevents pro- 
cessing of CPP32 as early as 18 h post stimulation and cleav- 
age of PARP at 30-h culture, which is prior to expression of 
Bcl-2, the ability of anti-CD40 to subvert ionomycin-triggered 
activation of CPP32 and subsequent cleavage of PARP occurs 
independently of Bcl-2 expression. 
By contrast, co-culture of Ramos-BL B cells with anti-IgM 
and anti-CD40 induces detectable xpression of Bcl-2 by 24 h 
post stimulation, suggesting that anti-IgM-triggered signal 
transduction events impinge upon and amplify the CD40-trig- 
gered biochemical events that lead to expression of Bcl-2. 
Since this induction of Bcl-2 expression precedes sIgM-trig- 
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Fig. 4. FACScan dot-blot light scatter profiles: zVAD- fmk inhibits ionomycin- and anti-IgM-triggered apoptosis in Ramos-BL B cells. Ramos- 
BL B cells (3 x 105cells/ml) were cultured for 48 h alone or with ionomycin (1 ktg/ml) or with anti-IgM (20 pg/ml) in the absence or presence of 
zVAD- fmk (100 lutM) and apoptosis was assessed by flow cytometry. The viable population contains cells with relatively high forward-scatter 
and low side-scatter properties while cells undergoing apoptosis appear in the low-forward-scatter/high-side-scatter zone. The results of one ex- 
periment, representative of three, are shown. 
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Fig. 5. zVAD-fmk inhibits ionomycin- and anti-IgM-triggered CPP32 processing and PARP cleavage in Ramos-BL B cells. Ramos-BL B cells 
(3 X 105cells/ml) were cultured for 24 h or 48 h alone or with ionomycin (1 p-g/ml) or with anti-IgM (20 p-g/ml) in the absence or presence of 
anti-CD40 (1 p-g/ml) or zVAD-fmk (100 p.M) and expression of the CPP32 proform and of PARP was determined by immunoblotting. The re- 
sults of one experiment, representative of three, are shown. 
gered processing of CPP32, which does not become apparent 
until 30 h, it is possible that Bcl-2 may prevent CPP32 pro- 
cessing and activation in this scenario. However, the anti- 
CD40-mediated inhibition of sIgM-triggered PARP cleavage 
is likely to be Bcl-2-independent since anti-IgM triggers clea- 
vage of PARP at 18 h, possibly in a CPP32-independent man- 
ner, prior to anti-CD40-triggered xpression of Bcl-2. 
3.4. z VAD-fmk inhibits ionomycin- and anti-Ig M-triggered 
CPP32 processing, PARP cleavage and apoptosis, but 
not growth arrest, in Ramos-BL B cells 
The data collected thus far demonstrate hat both the cal- 
cium ionophore ionomycin and cross-linking sIgM trigger ac- 
tivation of CPP32 and cleavage of PARP and may thus lead 
to the apoptosis of Ramos-BL B cells. In order to test this 
hypothesis further, we examined the effect of zVAD-fmk, an 
irreversible, cell-permeable tripeptide inhibitor of ICE family 
cysteine proteases [31,32], on ionomycin- and anti-IgM-trig- 
gered processing of CPP32, PARP cleavage and on growth 
arrest and apoptosis in Ramos-BL B cells. 
The results presented in Table 3 demonstrate hat following 
48-h culture, zVAD-fmk (10-100 gM) slightly increases basal 
levels of [aH]thymidine incorporation but has little or no effect 
on ionomycin- and anti-IgM-triggered growth arrest in Ra- 
mos-BL B cells. By marked contrast zVAD-fmk, which fails to 
affect basal levels of apoptosis, significantly reduces both io- 
nomycin- and anti-IgM-triggered levels of apoptosis in a dose- 
dependent fashion (Table 4; Fig. 4). However, the maximal 
dose of 100 gM zVAD-fmk used here does not quite reduce 
ionomycin- and anti-IgM-triggered levels of apoptosis to 
those of the control, which suggests that another factor, in- 
dependent of the ICE family of enzymes, contributes to the 
execution of apoptosis in Ramos-BL B cells. We confirmed 
that CPP32 is a critical component of ionomycin- and anti- 
IgM-triggered apoptosis in Ramos-BL B cells by demonstrat- 
ing that zVAD-fmk, used at a concentration of 100 gM, can 
at least partially prevent both ionomycin- and anti-IgM-trig- 
gered processing of CPP32 and cleavage of PARP at 24 h and 
at 48 h post stimulation; however, zVAD-fmk is by no means 
as effective as treatment with anti-CD40 in the prevention of 
these processes (Fig. 5). 
Taken together, these data suggest hat both ionomycin- 
and anti-IgM-triggered apoptosis, but not growth arrest, is 
at least partially dependent on the activity of members of 
the ICE family of cysteine proteases. 
4. Discussion 
The process of cell death by apoptosis is of fundamental 
importance in the regulation of the immune system where it is 
involved in the selection of both immature T and B lympho- 
cytes bearing functional AgR to non-self and in the selection 
of mature B cells bearing high-affinity AgR for non-self dur- 
ing maturation of the humoral immune response [39]. The 
latter of these scenarios, in which mature B cells undergo 
selection by apoptosis at the GC site, is represented here by 
the EBV-genome-negative Ramos-BL cell line [30]. In such 
cellular populations ubject o regulation through apoptosis, 
dysregulation of the apoptotic mechanism can have devastat- 
ing consequences by contributing to the pathogenesis of ma- 
lignancy. Indeed two tumours arising at the GC site, BL and 
follicular centre cell lymphoma, show aberrations in their abil- 
ity to undergo apoptosis [39]. 
In this report we demonstrate hat in a physiological system 
of stimulus-triggered apoptosis, endogenous members of the 
new and growing family of ICE cysteine proteases [4,38] act as 
critical effectors of apoptotic death. Our evidence for this con- 
clusion is two-fold. First, zVAD-fmk, an inhibitor of ICE fam- 
ily protease activity [31,32], rescues Ramos-BL B cells from 
both calcium ionophore- and AgR-triggered apoptosis (Table 
4; Fig. 4). However, zVAD-fmk fails to completely reduce 
both ionomycin- and anti-IgM-driven death to control levels 
of apoptosis and thus suggests the existence of a mediator(s)/ 
effector(s) of Ramos-BL B cell apoptosis which does not be- 
long to, nor is regulated by, the ICE family of cysteine pro- 
teases. Li et al. [40] and Kuida et al. [41] recently demonstrated 
that mice deficient in ICE develop normally and that their 
thymocytes and macrophages undergo apoptosis in response 
to dexamethasone and ionising radiation but not to anti-Fas 
antibody. While these data can be interpreted to indicate the 
redundancy of multiple members of the ICE family in their 
apoptotic function [38,40,41], they do not preclude the possi- 
bility of a route to apoptotic death independent of the ICE 
cysteine proteases. In toto, our data suggest that both calcium 
ionophore and anti-IgM trigger Ramos-BL B cell apoptosis 
primarily through an ICE-family-dependent pathway. 
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Our second line of evidence derives from the direct study of 
CPP32/Yama (Fig. 1). Engaging the AgR of Ramos-BL B 
cells triggers evident CPP32 processing approximately 6 h 
prior to the onset of apoptosis at 30-h culture. Thus, the 
activation of CPP32/Yama to apopain and subsequent cleav- 
age of its substrates, uch as PARP [11,12,18,19,26], may de- 
liver the final fatal blow in an amplifying cascade of protease 
activity. AgR-triggered egradation of PARP is apparent at 
18 h and thus precedes the activation of CPP32/Yama at 24 h; 
the cleavage of PARP then appears to be greatly accelerated 
following activation of CPP32/Yama (Fig. 2). It follows that 
signals transduced through the AgR of Ramos-BL B cells 
must result in the activation of a member(s) of the ICE fa- 
mily, prior to the activation of CPP32/Yama, able to cleave 
PARP such as TX [15,42], Mch-2 [18] or Mch-3 [19]. This 
process of AgR-triggered, CPP32/Yama-independent degrada- 
tion of PARP is in itself insufficient to trigger apoptosis and 
likely indicates the ability of cellular mechanisms to repair 
initial proteolytic damage; a critical point then appears to 
be attained following the activation of CPP32/Yama when 
proteolysis likely outpaces repair and cellular collapse into 
apoptotic death ensues [4]. Although it is known that ICE 
can process CPP32/Yama to its active apopain form [9-12], 
the precise molecular mechanisms by which the activity of 
CPP32/Yama, and indeed the ICE family, is regulated remains 
to be elucidated. 
In the Ramos-BL B cell model, 24 h elapses between AgR 
ligation and CPP32 activation suggesting that, as for cellular 
entry into apoptosis [43], the regulation of cysteine protease 
activity may be related to progression through the cell cycle. 
The complexity of the regulatory mechanisms likely to be 
operating here is further highlighted by our observations 
that ionomycin-triggered activation of CPP32/Yama at 18 h 
precedes cleavage of PARP at 30 h; these data, when consid- 
ered in conjunction with the AgR-driven time course of 
CPP32/Yama activation and PARP degradation, suggest 
that the initial biochemical events triggered by an apoptotic 
stimulus may influence the ultimate substrate preference of 
CPP32/Yama. As well as acting on PARP, CPP32/Yama 
has recently been shown to cleave sterol regulatory element 
binding protein-1 (SREBP-1) and SREBP-2 in vitro, although 
the significance of this observation to the apoptotic mechan- 
ism is not known [44]. 
Calcium ionophore- and AgR-triggered activation of 
CPP32/Yama and degradation of PARP is arrested by signals 
transduced through the surface CD40 of Ramos-BL B cells; 
this CD40-mediated inhibition of cleavage appears to be of a 
greater efficacy than that observed for zVAD-fmk (Fig. 5). 
Although ligation of CD40 is known to trigger activation of 
the protein tyrosine kinase Lyn and of phosphatidylinositol 3- 
kinase, stress-activated protein kinases and NF-~B [45-47], the 
molecular mechanism(s) by which anti-CD40 elicits such ef- 
fective inhibition of the apoptotic pathway is unknown. It is 
clear that while both anti-CD40 and zVAD-fmk rescue Ra- 
mos-BL B cells from ionomycin- and AgR-driven apoptosis, 
only anti-CD40 is able to alleviate the growth arrest observed 
following such treatments (Tables 14). These data indicate 
that pathways for growth arrest and apoptosis are distinct and 
this is supported by data demonstrating that AgR-triggered 
growth arrest precedes both CPP32/Yama processing and 
apoptosis. 
It has been postulated that Bcl-2 may afford protection 
against apoptosis by inhibiting the activity of ICE family 
members [38]. In Ramos-BL B cells, anti-CD40-mediated in-
hibition of ionomycin-triggered CPP32/Yama activation and 
PARP cleavage together with AgR-triggered, CPP32/Yama- 
independent, degradation of PARP precedes Bcl-2 expression 
(Fig. 3). Thus, CD40-mediated survival signals must subvert 
the ionomycin- and AgR-triggered apoptotic pathways up- 
stream from activation of ICE family members by proteolysis. 
However, co-culture of Ramos-BL B cells with anti-IgM and 
anti-CD40 triggers Bcl-2 expression prior to AgR-triggered 
processing of CPP32/Yama; in this scenario, inhibition of 
the apoptotic pathway mediated by CPP32/Yama may be co- 
incident with or alternatively dependent upon expression of 
Bcl-2. 
In summary, we have demonstrated in a physiological sys- 
tem of stimulus-triggered apoptosis that activation of endo- 
genous members of the ICE family, including CPP32/Yama, 
and cleavage of the death substrate PARP act as critical ef- 
fectors of apoptosis. 
Acknowledgements: The work reported here was supported by The 
Department of Biochemistry, The University of Oxford, Oxford 
(UK), the Leukaemia Research Fund (UK) and by a Royal Society 
(UK) equipment grant. We would also like to thank Professor W.C. 
Earnshaw of The University of Edinburgh, Edinburgh (UK) for the 
kind gift of murine anti-PARP antibody (C-2-10). We are also grate- 
ful to Dr. D.Y. Mason of The John Radcliffe Hospital, Oxford (UK) 
for the generous gift of murine anti-Bcl-2 monoclonal ntibody. 
References 
[1] Wyllie, A.H. (1980) Int. Rev. Cytol. 68, 251 307. 
[2] Raft, M.C. (1992) Nature 356, 397-400. 
[3] Cohen, J.J. (1993) Immunol. Today 14, 12(~130. 
[4] Martin S.J. and Green, D.R. (1995) Cell 82, 349 352. 
[5] Hengartner, M.O. and Horvitz, H.R. (1994) Curr. Opin. Genet. 
Dev. 4, 581-586. 
[6] Yuan, J., Shaham, S., Ledoux, S., Ellis, H.M. and Horvitz, H.R. 
(1993) Cell 75, 641-652. 
[7] Miura, M., Zhu, H., Rotello, R., Hartwieg, E.A. and Yuan, J. 
(1993) Cell 75, 653~660. 
[8] Cerretti, D.P., Kozlosky, C.J., Mosley, B., Nelson, N., Ness, 
K.V., Greenstreet, T.A., March, C.J., Kronheim, S.R., Druck, 
T., Cannizzaro, L.A., Huebner, K. and Black, R.A. (1992) 
Science 256, 97-100. 
[9] Thornberry, N.A., Bull, H.G., Calaycay, J.R., Chapman, K.T., 
Howard, A.D., Kostura, M.J., Miller, D.K., Molineaux, S.M., 
Weidner, J.R., Aunins, J., Elliston. K.O., Ayala, J.M., Casano, 
F.J., Chin, J., Ding, G.J.-F., Egger, L.A., Gaffney, E.P., Limju- 
co, G., Palyha, O.C., Raju, S.M., Rolando, A.M., Salley, J.P., 
Yamin, T-T., Lee, T.D., Shively, J.E., MacCross, M., Mumford, 
R.A., Schmidt, J.A. and Tocci, M.J. (1992) Nature 356, 768-774. 
[10] Fernandes-Alnemri, T., Litwack, G. and Alnemri, E.S. (1994) J. 
Biol. Chem. 269, 30761 30764. 
[11] Tewari, M., Quan, L.T., O'Rourke, K., Desnoyers, S., Zeng, Z., 
Beidler, D.R., Poirier, G.G., Salvesen, G.S. and Dixit, V.M 
(1995) Cell 81, 801-809. 
[12] Nicholson, D.W., Ali, A., Thornberry, N.A., Vaillancourt, J.P., 
Ding, C.K., Gallant, M., Gareau, Y., Griffin, P.R., Labelle, M., 
Lazebnik, Y.A., Munday, N.A., Raju, S.M., Smulson, M.E., 
Yamin, T.-T., Yu, V.L. and Miller, D.K. (1995) Nature 376, 
37-43. 
[13] Kumar, S., Kinoshita, M., Noda, M., Copeland, N.G. and Jen- 
kins, N.A. (1994) Genes Dev. 8, 1613-1626. 
[14] Wang, L., Miura. M., Bergeron, L., Zhu, H. and Yuan, J. (1994) 
Cell 78, 739 750. 
[15] Faucheu, C., Diu, A., Chan, A.W.E., Blanchet, A.-M., Miossec, 
C., Herve, F., Collard-Dutilleul, V., Gu, Y., Aldape, R. A., 
Lippke, J.A., Rocher, C., Su, M.S.-S., Livingston, D.J., Hercend, 
T. and Lalanne, J.-L. (1995) EMBO J. 14, 1914-1922. 
122 
[16] Kamens, J., Paskind, M., Hugunin, M., Talanian, R.V., Allen, 
H., Banach, D., Bump, N., Hackett, M., Johnston, C.G., Li, P., 
Mankovich, J.A., Terranova, M. and Ghayur, T. (1995) J. Biol. 
Chem. 270, 15250-15256. 
[17] Munday, N.A., Vaillancourt, J.P., Ali, A., Casano, F.J., Miller, 
D.K., Molineaux, S.M., Yamin, T.-T., Yu, V.L. and Nicholson, 
D.W. (1995) J. Biol. Chem. 270, 15870-15876. 
[18] Fernandes-Alnemri, T., Litwack, G. and Alnemri, E.S. (1995) 
Cancer Res. 55, 2737-2742. 
[19] Fernandes-Alnemri, T., Takahashi, A., Armstrong, R., Krebs, J., 
Fritz, L., Tomaselli, K.J., Wang, L., Yu, Z., Croce, C.M., Sal- 
veson, G., Earnshaw W.C., Litwack, G. and Alnemri, E.S. (1995) 
Cancer Res. 55, 6045-6052. 
[20] Duan, H., Chinnaiyan, A.M., Hudson, P.L., Wing, J.P., He, W.- 
W. and Dixit, V.M. (1996) J. Biol. Chem. 271, 1621 1625. 
[21] Los, M., van de Craen, M., Penning. L.C., Schenk, H., Westen- 
dorp, M., Baeuerle, P.A., Droge, W., Krammer, P.H., Fiers, W. 
and Schulze-Osthoff, K. (1995) Nature 275, 81-83. 
[22] Enari, M., Hug, H. and Nagata, S. (1995) Nature 375, 78 81. 
[23] Neamati, N., Fernandez, A., Wright, S., Kiefer, J. and McCon- 
key, D.J. (1995) J. Immunol. 154, 3788-3795. 
[24] Lazebnik, Y.A., Takahashi, A., Moir, R.D., Goldman, R.D., 
Poirier, G.G., Kaufmann, S.H. and Earnshaw, W.C. (1995) 
Proc. Natl. Acad. Sci. USA (1995) 92, 9042-9046. 
[25] Wright, S.C., Wei, Q.S., Zhong, J., Zheng, H., Kinder, D.H. and 
Larrick, J.W. (1994) J. Exp. Med. 180, 2113-2123. 
[26] Kaufmann, S.H., Desnoyers, S., Ottaviano, Y., Davidson, N.E. 
and Poirier, G.G. (1993) Cancer Res. 53, 3976-3985. 
[27] MacLennan, I.C.M. and Gray, D. (1986) Immunol. Rev. 91, 61 
85. 
[28] MacLennan, I.C.M., Liu, Y.-J. and Ling, N.R. (1988) Curr. 
Topics Microbiol. Immunol. 141, 138-148. 
[29] Liu, Y.-J., Joshua, D.E., Williams, G.T., Smith, C.A., Gordon, J. 
and MacLennan, I.C.M. (1989) Nature 342, 929--931. 
[30] Kelly, K. and Knox, K.A. (1995) Cell. Immunol. 166, 93-102. 
[31] Dolle, R.E., Hoyer, D., Prasad, C.V.C., Schmidt, S.J., Helaszek, 
C.T., Miller, R.E. and Ator, M.A. (1994) J. Med. Chem. 37, 563 
564. 
[32] Pronk, G.S., Ramer, K., Amiri, P. and Williams, L.T. (1996) 
Science 271,808-810. 
S. An, K.A. KnoxIFEBS Letters 386 (1996) 115-122 
[33] Klein, G., Giovanella, B., Westmen, A., Stehlin, J. and Mum- 
ford, D. (1975) Int. Virol. 5, 319 334. 
[34] Magrath, I.T., Pizzo, P.A., Whang-Peng, J. Douglass, E.C., Ala- 
baster, O., Gerber, P., Freeman, C.B. and Nivikovs, L. (1980) J. 
Natl. Cancer Inst. 64, 465-476. 
[35] Magrath, I.T., Freeman, C.B., Pizzo, P.A., Gadek, J., Jaffe, E., 
Santaella, M., Hammer, C., Frank, M., Reaman, G. and Novi- 
kos, L. (1980) J. Natl. Cancer Inst. 64, 477- 483. 
[36] Knox, K.A., Finney, M., Milner, A.E., Gregory, C.D., Wakelam, 
M.J.O., Michell, R.H. and Gordon, J. (1992) Int. J. Cancer 52, 
959 966. 
[37] Lazebnik, Y.A., Kaufmann, S.H., Desnoyers, S., Poirier, G.G. 
and Earnshaw, W.C. (1994) Nature 371, 346-347. 
[38] Kumar S. (1995) Trends Biochem. Sci. 20, 198-202. 
[39] Knox, K.A. and Gordon. J. (1995) in: Apoptosis and the Im- 
mune Response (Gregory, C.D., Ed.), pp. 313 339. Wiley-Liss, 
Chichester. 
[40] Li, P., Allen, H., Banerjee, S., Franklin, S., Herzog, L., Johnston, 
C., McDowell, J., Paskind, M., Rodman, L., Salfeld, J., Towne, 
E., Trcey, D., Wardell, S., Wei, F.-Y., Wong, W., Kamen, R. and 
Seshadri, T. (1995) Cell 80, 401-411. 
[41] Kuida, K., Lippke, J.A., Ku, G., Harding, M.W., Livingston, 
D.J., Su, M.S.-S. and Flavell, R.A. (1995) Science 267, 2000- 
2003. 
[42] Gu, Y., Sarnecki, C., Aldape, R.A., Livingston, D.J. and Su, 
M.S.-S. (1995) J. Biol. Chem. 270, 18715-18718. 
[43] Evan, G., Brown, L., Whyte, M. and Harrington, E. (1995) Curr. 
Opin. Cell Biol. 7, 825 834. 
[44] Wang., X, Pai, J.-T., Wiedenfeld, E.A., Medina, J.C., Slaughter, 
C.A., Goldstein, J.L. and Brown, M.S. (1995) J. Biol. Chem. 270, 
18044~ 18050. 
[45] Ren, C.L., Morio, T., Fu, S.F. and Geha, R.S. (1994) J. Exp. 
Med. 179, 673-680. 
[46] Berberich, I., Shu, G.L. and Clarke, E.A. (1994) J. Immunol. 
153, 4357-4366. 
[47] Berberich, I., Shu, G., Siebelt, F., Woodgett, J.R., Kyriakis, J.M. 
and Clark, E.A. (1996) EMBO J. 15, 92 101. 
